During the mean follow-up of 17 ± 7 months, there were 26 deaths 20% and 21 nonfatal cardiovascular events 16%.
Durante el seguimiento medio de 17 ± 7 meses, hubo 26 fallecimientos 20% y 21 eventos cardiovasculares no fatales 16%.